• Original articles • Previous Articles     Next Articles

Antitumor activity and biodistribution of DHA-NLC formulation in sarcoma 180-bearing mice

Xiaoyun Zhang*, Hua Qiao, Peng Zhao, Jingman Ni, Yanbin Shi   

  1. 1. School of Pharmacy, Lanzhou University, Gansu 730000, China
    2. Department of Pharmaceutics, the First Hospital of Lanzhou University, Gansu 730000, China
    3. Department of Oncology, the First Hospital of Lanzhou University, Gansu 730000, China
  • Received:2012-09-21 Revised:2012-11-19 Online:2013-07-10 Published:2013-07-10
  • Contact: Xiaoyun Zhang*


Lipid nanoparticles have become attractive for its prominent properties recent years. In this paper, in vivo anti-tumor efficacy of nanostructured lipid carrier of dihydroartemisinin (DHA-NLC) were evaluated in sarcoma 180-bearing mice model through intraperitoneal (i.p.) administration. In vivo biodistribution was also investigated in Kunming mice bearing S180. Results demonstrated that the intraperitoneally injected DHA-NLC could significantly inhibit tumor growth at the dose levels of 20, 40 and 80 mg/kg, and their inhibition rates were 71.24%, 79.20% and 85.74%, respectively. The biodistribution of DHA after intraperitoneal injection of DHA-NLC in S180-bearing mice is remarkably different from the DHA solution. Therefore, DHA encapsulated in NLC does demonstrate superior anticancer effect to DHA suspension on S180-bearing mice at the same dose and displayed a dose-dependent antitumor efficacy.

Key words: Nanostructured lipid carrier, Antitumor, Sarcoma 180, Biodistribution

CLC Number: